Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Caprion Pharmaceuticals Inc. is a clinical-stage biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. Caprion’s clinical-stage programs include Shigamabs®, a product for the treatment of Shigatoxin-producing E. coli bacterial infections, and CAP-232, a targeted therapy with potential efficacy in multiple oncology indications. CellCarta®, Caprion’s proprietary proteomics technology, provides Caprion with an effective means to identify novel drug targets, predict which therapeutics may be safer and more efficacious, and identify which patients may benefit most from a particular therapy. ( www.caprion.com )
Caprion Pharmaceuticals Inc.
7150 Alexander Fleming
Montréal, Québec H4S 2C8
Canada
Tel: (514) 940-3610
Fax: (514) 336-2343